Algert Global LLC Invests $343,000 in Cambrex Co. (CBM) Stock
Algert Global LLC bought a new position in shares of Cambrex Co. (NYSE:CBM) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 7,149 shares of the biotechnology company’s stock, valued at approximately $343,000.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. LSV Asset Management grew its stake in Cambrex by 1,020.5% during the 4th quarter. LSV Asset Management now owns 62,750 shares of the biotechnology company’s stock worth $3,011,000 after purchasing an additional 57,150 shares in the last quarter. Front Row Advisors LLC purchased a new stake in Cambrex during the 4th quarter worth about $815,000. Mutual of America Capital Management LLC purchased a new stake in Cambrex during the 4th quarter worth about $1,223,000. Dupont Capital Management Corp purchased a new stake in Cambrex during the 4th quarter worth about $440,000. Finally, Congress Asset Management Co. MA lifted its holdings in Cambrex by 4.2% during the 4th quarter. Congress Asset Management Co. MA now owns 1,482,826 shares of the biotechnology company’s stock worth $71,176,000 after buying an additional 59,600 shares during the last quarter.
A number of brokerages have issued reports on CBM. William Blair began coverage on Cambrex in a report on Tuesday, January 16th. They set an “outperform” rating for the company. Zacks Investment Research raised Cambrex from a “strong sell” rating to a “hold” rating in a report on Monday, January 15th. Finally, Craig Hallum reaffirmed a “buy” rating and set a $60.00 price target (down from $70.00) on shares of Cambrex in a report on Tuesday, October 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $60.50.
ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/algert-global-llc-invests-343000-in-cambrex-co-cbm-stock/1847355.html.
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.